AbbVie Inc
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 2013年1月2日
- 従業員数
- 57,000
- 公式サイト
- www.abbvie.com
総合バリュエーションレンジ · 保守的 $150–$175 / 妥当 $180–$205 / 楽観的 $210–$235。$256.91 時点で 楽観的シナリオの上限を超過 · 将来の成長を先取り。
レポート公開時 $212.3（2026年5月21日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
沿革
AbbVie Inc. was incorporated in 2012 and completed its IPO on January 2, 2013. The research-based biopharmaceutical company is headquartered in North Chicago, Illinois, and employs about 57,000 people. After Humira lost US exclusivity and came under pressure beginning in 2023, Skyrizi and Rinvoq grew into its new core products. The company expanded through acquisitions, with Allergan bringing Botox and the aesthetics and neuroscience businesses into its portfolio, followed by the Cerevel acquisition (about $8.3 billion net cash, completed in 2024) and ImmunoGen (about $9.2 billion net consideration).
業界での地位
AbbVie is a global innovative biopharmaceutical company operating as a single worldwide business segment spanning immunology, neuroscience, oncology, aesthetics, eye care and other products. In 2025 its revenue reached $61.16 billion, with Skyrizi and Rinvoq together contributing about 42% of revenue. It sells largely to wholesalers, distributors and other channels, with US drug sales heavily dependent on three wholesalers: McKesson, Cardinal Health and Cencora. It competes in immunology with Johnson & Johnson, Eli Lilly and Novartis, and in oncology with Roche, AstraZeneca, Bristol Myers Squibb and Merck, and holds market-leading positions in aesthetics.
この銘柄のレポートはお使いの言語でまだありません。